



Sheet 1 of 6

Form PTO-1449 Modified		Docket No. TJU0006-101	Serial No. 10/695,578
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Scott A. Waldman et al.	
U.S. Department of Commerce Patent and Trademark Office		Filing Date 10/27/2003	Group To Be Determined
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
<i>BB</i>	AA	Almenoff et al., "Induction of heat-stable enterotoxin receptor activity by a human Alu repeat," <i>J. Biol. Chem.</i> , 1994, 269(24), 16610-16617	
	AB	Berd et al., "Immunization with Haptenized, Autologous Tumor Cells Induces Inflammation of Human Melanoma Metastases", <i>Cancer Res.</i> , 1991, 51, 2731-2734	
	AC	Berd et al., "Induction of Cell-mediated Immunity to Autologous Melanoma Cells and Regression of Metastases after Treatment with a Melanoma Cell Vaccine Preceded by Cyclophosphamide", <i>Cancer Res.</i> , 1986, 46, 2572-2577	
	AD	Carrithers et al., "Escherichia coli heat-stable toxin receptors in human colonic tumors," <i>Gastroenterology</i> , 1994, 107, 1653-1661	
	AE	Carrithers et al., "Escherichia coli heat-stable enterotoxin receptors. A novel marker for colorectal tumors," <i>Diseases Colon & Rectum</i> , 1996, 39(2), 171-181	
	AF	Francis et al., Peptide Vaccines Based on Enhanced Immunogenicity of Peptide Epitopes Presented with T-Cell Determinants or Hepatitis B Core Protein", <i>Methods in Enzymol.</i> , 1989, 178, 659-676	
	AG	MacLean et al., "Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant", <i>Cancer Immunol. Immunother.</i> , 1993, 36, 215-222	
	AH	Miller et al., "The Induction of Hapten-Specific T Cell Tolerance by Using Hapten-Modified Lymphoid Cells", <i>J. Immunol.</i> , 1976, 117(5:1), 1519-1526	
	AI	Rudner et al., "Regulation of cell signaling by the cytoplasmic domains of the heat-stable enterotoxin receptor: Identification of autoinhibitory and activating motifs", <i>Proc. Natl. Acad. Sci.</i> , 1995, 92, 5169-5173	
	AJ	Sad et al., "Bypass of carrier-induced epitope-specific suppression using a T-helper epitope", <i>Immunology</i> , 1992, 76, 599-603	
	AK	Waldman et al., "Immunoaffinity Purification of Soluble Guanylyl Cyclase", <i>Methods Enzymol.</i> , 1991, 195, 391-396	
EXAMINER	<i>E. Stahr</i>		DATE CONSIDERED <i>8-25-06</i>

Form PTO-1449 Modified		Docket No. TJU0006-101	Serial No. 10/695,578
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Scott A. Waldman et al.	
U.S. Department of Commerce Patent and Trademark Office		Filing Date 10/27/2003	Group To Be Determined

U. S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass
	AL	4,022,878	05/10/77	Gross	424	1.5
	AM	4,329,281	05/11/82	Christenson et al.	260	112 B
	AN	4,526,716	07/02/85	Stevens	260	112.5 R
	AO	4,736,866	04/12/88	Leder et al.	800	1
	AP	4,873,191	10/10/89	Wagner et al.	435	172.3
	AQ	4,945,050	07/31/90	Sanford et al.	435	172.1
	AR	5,017,487	05/21/91	Stunnenberg et al.	435	172.3
	AS	5,037,645	08/06/91	Strahilevitz	424	85.8
	AT	5,112,606	05/12/92	Shiosaka et al.	530	389.2
	AU	5,352,775	10/04/94	Albertsen et al.	536	23.1
	AV	5,518,888	05/21/96	Waldman	435	7.23
	AW	5,601,990	02/11/97	Waldman	435	7.23

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO
	AX	WO 90/11092	10/04/90	PCT	X	
	AY	WO 95/11694	05/04/95	PCT	X	

EXAMINER

DATE CONSIDERED

8-25-06

Form PTO-1449 Modified		Docket No. TJU0006-101	Serial No. 10/695,578
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Scott A. Waldman et al.	
U.S. Department of Commerce Patent and Trademark Office		Filing Date 10/27/2003	Group To Be Determined

U. S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass
<i>SP</i>	AA	5,518,888	5/21/96	Waldman et al.	435	7.23
	AB	5,601,990	2/11/97	Waldman et al.	435	7.23
	AC	5,731,159	3/24/98	Waldman et al.	435	7.23
	AD	5,879,656	3/9/99	Waldman et al.	424	149
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					


FOREIGN PATENT DOCUMENTS

Examiner Initial						
	AK					
	AL					
	AM					
	AN					
	AO					

EXAMINER *SP Geller*

DATE CONSIDERED

8.25.06



PTO/SB/08a (08-03)

Approved for use through 07/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-278

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary.)


Shee

of 6

<i>Complete If Known</i>	
<i>Application Number</i>	10/695,578
<i>Filing Date</i>	October 27, 2003
<i>First Named Inventor</i>	Scott A. Waldman
<i>Art Unit</i>	To Be Determined
<i>Examiner Name</i>	To Be Determined
<i>Attorney Docket Number</i>	TJU0006-101 (WAL_SCO_005)

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	Sep. 26, 06
--------------------	---	-----------------	-------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		<i>Application Number</i>	10/695,578
(Use as many sheets as necessary)		<i>Filing Date</i>	October 27, 2003
		<i>First Named Inventor</i>	Scott A. Waldman
		<i>Art Unit</i>	To Be Determined
		<i>Examiner Name</i>	To Be Determined
Sheet	5	of	6
		<i>Attorney Docket Number</i>	TJU0006-101 (WAL_SCO_005)

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	BD	Banchereau et al., "Immune and clinical responses in patient with metastatic melanoma to CD34 ⁺ progenitor-derived dendritic cell vaccine," <i>Cancer Research</i> (2001) 61:6451-6458.		
	BE	Bellone et al., "Cancer immunotherapy: synthetic and natural peptides in the balance," <i>Immunology Today</i> (1999) 20(10):457-462.		
	BF	Carrithers et al., "Escherichia coli heat-stable toxin receptors in human colonic tumors," <i>Gastroenterology</i> (1994) 107:1653-1661.		
	BG	Celis et al., "Identification of potential CTL epitopes of tumor-associated antigen MAGE-1 for five common HLA-A alleles," <i>Molecular Immunology</i> (1994) 31(18):1423-1430.		
	BH	Disis et al., "Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein," <i>J. of Immunology</i> (1996) 156:3151-3158.		
	BI	Foon et al., "Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen," <i>Journal of Clinical Oncology</i> (1999) 17(9):2889-2895.		
	BJ	Herbert et al., <i>The Dictionary of Immunology</i> , Academic Press, 4 th ed. (1995).		
	BK	Greenspan et al., "Defining epitopes: It's not as easy as it seems," <i>Nature Biotechnology</i> (1999) 7:936-937.		
	BL	Gura "Systems for identifying new drugs are often faulty," <i>Science</i> (1997) 278:1041-1042.		
	BM	Mallo et al., "Expression of the Cdx1 and Cdx2 homeotic genes leads to reduced malignancy in colon cancer-derived cells," <i>J. Biological Chemistry</i> (1998) 273(22):14030-14036.		
	BN	Nelson et al., <i>J. Nat'l. Can. Inst.</i> (1996) 88(8):468-488.		

Examiner Signature		Date Considered	8-26-06
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Application Number</i>	10/695,578
(Use as many sheets as necessary)				<i>Filing Date</i>	October 27, 2003
				<i>First Named Inventor</i>	Scott A. Waldman
				<i>Art Unit</i>	To Be Determined
				<i>Examiner Name</i>	To Be Determined
Sheet	6	of	6	Attorney Docket Number	TJU0006-101 (WAL_SCO_005)

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
<i>SW</i>	BO	Reynolds et al., "Vaccine-induced CD8+ T-cell responses to MAGE-3 correlate with clinical outcome in patients with melanoma," <i>Clinical Cancer Research</i> (2003) 9:657-662.		
	BP	Singh et al., "Isolation and expression of a guanylate cyclase-coupled heat stable enterotoxin receptor cDNA from a human colonic cell line," <i>Biochem. Biophys. Res. Comm.</i> (1991) 179(3):1455-1463.		
	BQ	Smith "Cancer and the immune system," <i>Pediatr Clin North Am.</i> (1994) 41(4) 841-850.		
	BR	Spitler "Cancer vaccines: the interferon analogy," <i>Cancer Biotherapy</i> (1995) 10:1-3.		
	BS	Welzien HU "Renaissance for hapten-specific T lymphocytes: implications for basic and applied research," <i>Z Naturforsch [C]</i> (1992) 47(5-6):323-328.		
	BT	Miller et al., "Improved survival of patients with Melanoma with an antibody response to immunization of a polyvalent melanoma vaccine," <i>Cancer</i> (1995) 75(2):495-502.		

Examiner Signature	<i>Scott A. Waldman</i>	Date Considered	8-26-06
--------------------	-------------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.